Novavax (NVAX) Weakness Over Increased Spending is Unwarranted - FBR

March 1, 2016 7:22 AM

FBR Capital analyst, Vernon Bernardino, reiterated his Outperform rating as vaccine developer Novavax (NASDAQ: NVAX) reported 4Q15 financial results ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found